CNCR icon

ETF Series Solutions Trust Range Cancer Therapeutics ETF

12.35 USD
+0.03
0.24%
At close Dec 24, 4:00 PM EST
1 day
0.24%
5 days
-2.14%
1 month
-10.44%
3 months
-18.16%
6 months
-12.22%
Year to date
-9.46%
1 year
-8.59%
5 years
-49.51%
10 years
-50.78%
0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

5.43% less ownership

Funds ownership: 10.54% [Q2] → 5.11% (-5.43%) [Q3]

15% less funds holding

Funds holding: 13 [Q2] → 11 (-2) [Q3]

46% less capital invested

Capital invested by funds: $1.68M [Q2] → $901K (-$778K) [Q3]

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Research analyst outlook

We haven’t received any recent analyst ratings for CNCR.

Financial journalist opinion

Positive
ETF Trends
1 month ago
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.
Disruptive Theme of the Week – Breakthroughs in Medicine
Neutral
Zacks Investment Research
2 months ago
The Zacks Analyst Blog SFYX, CNCR, FXN and DIV
SFYX, CNCR, FXN and DIV are included in this Analyst Blog.
The Zacks Analyst Blog SFYX, CNCR, FXN and DIV
Positive
Zacks Investment Research
2 months ago
4 Solid ETFs Under $20 for Your Portfolio
Low-priced ETFs could be attractive for investors as these enable them to buy more shares instead of just a handful of higher-priced shares for the same amount.
4 Solid ETFs Under $20 for Your Portfolio
Positive
Zacks Investment Research
3 months ago
5 ETFs That Led the Rebound on Monday
Wall Street roars back from its biggest weekly losses of the year, driven by bargain hunting and looming Fed rate cuts.
5 ETFs That Led the Rebound on Monday
Positive
Zacks Investment Research
3 months ago
Best-Performing ETF Areas of Past Week
Wall Street was upbeat last week on Fed rate cut hopes.
Best-Performing ETF Areas of Past Week
Positive
Zacks Investment Research
4 months ago
5 Top-Ranked ETFs to Buy at a Bargain
After a three-day rout, Wall Street staged a solid comeback as investors bought beaten-down stocks and recession fears eased. To tap the beaten-down prices, we have highlighted five ETFs from different corners that have declined over the past week and have a solid Zacks ETF Rank.
5 Top-Ranked ETFs to Buy at a Bargain
Positive
Zacks Investment Research
4 months ago
Best ETFs of Last Week
Wall Street offered a mixed performance last week.
Best ETFs of Last Week
Positive
Zacks Investment Research
5 months ago
5 Top ETFs of Last Week
Wall Street was moderately upbeat last week with the S&P 500, the Dow Jones and the Nasdaq gaining 0.87%, 1.6% and 0.3%, respectively. However, the small-cap index – the Russell 2000 – has advanced 6% as consumer inflation print came in at cooler-than-expected.
5 Top ETFs of Last Week
Neutral
ETF Trends
6 months ago
Last Week in ETFs: 8 New Defined Outcome ETFs Debut
Last week was a busy one for ETFs, with nine new ETFs launching on the first day of the week alone. Calamos, Innovator, AllianzIM, Direxion, Global X and ProShares were among the issuers rolling out new funds.
Positive
Zacks Investment Research
6 months ago
3 Top-Ranked ETFs Under $20 for Your Portfolio
Low-priced stocks could be attractive as these will enable them to buy more shares instead of just a handful of higher-priced shares for the same amount.
3 Top-Ranked ETFs Under $20 for Your Portfolio
Charts implemented using Lightweight Charts™